Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Cemiplimab + Ziv-Aflibercept for Uveal Melanoma
Recruiting1 awardPhase 2
Tampa, Florida
This trial is testing a combination of two drugs, Cemiplimab and Ziv-Aflibercept, to treat patients with metastatic uveal melanoma. Cemiplimab helps the immune system fight cancer, while Ziv-Aflibercept stops tumors from getting the blood they need to grow. The goal is to see if this combination can shrink or stop the growth of tumors.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service